Brushing up on the science of obesity with Rhythm Pharmaceuticals’ CEO
- blonca9
- Oct 19, 2023
- 1 min read
David Meeker describes his company’s focus on the melanocortin-4 receptor pathway and elaborates on data presented this week for hypothalamic obesity.